294 related articles for article (PubMed ID: 10069576)
21. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.
Rüb U; de Vos RA; Brunt ER; Sebestény T; Schöls L; Auburger G; Bohl J; Ghebremedhin E; Gierga K; Seidel K; den Dunnen W; Heinsen H; Paulson H; Deller T
Brain Pathol; 2006 Jul; 16(3):218-27. PubMed ID: 16911479
[TBL] [Abstract][Full Text] [Related]
22. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3.
Gales L; Cortes L; Almeida C; Melo CV; Costa MC; Maciel P; Clarke DT; Damas AM; Macedo-Ribeiro S
J Mol Biol; 2005 Oct; 353(3):642-54. PubMed ID: 16194547
[TBL] [Abstract][Full Text] [Related]
23. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
24. Prenatal diagnosis of Machado-Joseph disease/Spinocerebellar Ataxia Type 3 in Taiwan: early detection of expanded ataxin-3.
Tsai HF; Liu CS; Chen GD; Lin ML; Li C; Chen YY; Wang BT; Hsieh M
J Clin Lab Anal; 2003; 17(5):195-200. PubMed ID: 12938149
[TBL] [Abstract][Full Text] [Related]
25. Machado-Joseph disease gene product identified in lymphocytes and brain.
Wang G; Ide K; Nukina N; Goto J; Ichikawa Y; Uchida K; Sakamoto T; Kanazawa I
Biochem Biophys Res Commun; 1997 Apr; 233(2):476-9. PubMed ID: 9144561
[TBL] [Abstract][Full Text] [Related]
26. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
Gonçalves N; Simões AT; Cunha RA; de Almeida LP
Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
[TBL] [Abstract][Full Text] [Related]
27. CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration.
Liman J; Deeg S; Voigt A; Voßfeldt H; Dohm CP; Karch A; Weishaupt J; Schulz JB; Bähr M; Kermer P
J Neurochem; 2014 Jun; 129(6):1013-23. PubMed ID: 24548080
[TBL] [Abstract][Full Text] [Related]
28. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3.
Jeub M; Herbst M; Spauschus A; Fleischer H; Klockgether T; Wuellner U; Evert BO
Exp Neurol; 2006 Sep; 201(1):182-92. PubMed ID: 16765348
[TBL] [Abstract][Full Text] [Related]
29. Dynamic expression of Hsp27 in the presence of mutant ataxin-3.
Chang WH; Cemal CK; Hsu YH; Kuo CL; Nukina N; Chang MH; Hu HT; Li C; Hsieh M
Biochem Biophys Res Commun; 2005 Oct; 336(1):258-67. PubMed ID: 16126176
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains.
Evert BO; Vogt IR; Kindermann C; Ozimek L; de Vos RA; Brunt ER; Schmitt I; Klockgether T; Wüllner U
J Neurosci; 2001 Aug; 21(15):5389-96. PubMed ID: 11466410
[TBL] [Abstract][Full Text] [Related]
31. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
32. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
33. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
34. Altered expression of carbonic anhydrase-related protein XI in neuronal cells expressing mutant ataxin-3.
Hsieh M; Chang WH; Hsu CF; Nishimori I; Kuo CL; Minakuchi T
Cerebellum; 2013 Jun; 12(3):338-49. PubMed ID: 23184527
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3.
Evert BO; Vogt IR; Vieira-Saecker AM; Ozimek L; de Vos RA; Brunt ER; Klockgether T; Wüllner U
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1006-18. PubMed ID: 14575237
[TBL] [Abstract][Full Text] [Related]
36. Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.
Colomer Gould VF
NeuroRx; 2005 Jul; 2(3):480-3. PubMed ID: 16389311
[TBL] [Abstract][Full Text] [Related]
37. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
38. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
[TBL] [Abstract][Full Text] [Related]
39. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
Griffin JL; Cemal CK; Pook MA
Physiol Genomics; 2004 Feb; 16(3):334-40. PubMed ID: 14679302
[TBL] [Abstract][Full Text] [Related]
40. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.
Mueller T; Breuer P; Schmitt I; Walter J; Evert BO; Wüllner U
Hum Mol Genet; 2009 Sep; 18(17):3334-43. PubMed ID: 19542537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]